Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial

By afschroeder • March 3, 2026

Durstenfeld MS, Levkova-Clark M, Ms DL, Schaffer V, Abohashem S, Ma Y, Kawai K, Lu MT, Sereti I, Deeks SG, Tawakol A, Hsue PY. Rationale, design, and baseline characteristics of the Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection: EPIC-HIV Randomized Clinical Trial. Am Heart J. 2026 Feb 28:107400. doi: 10.1016/j.ahj.2026.107400. Epub ahead of print. PMID: 41771366.

Tags: arterial inflammation, Cardiology/Epi, Cholesterol, Clinical Trial, Coronary Atherosclerosis, HIV, PCSK9, Publications

P2Y12 Inhibitors and Mortality in Patients Hospitalized With Intracerebral Hemorrhage

Jin C, Song Y, Mac Grory B, Sun JL, Alhanti B, Fonarow GC, Schwamm LH, Sheth KN, Smith EE, Messé SR, Saver JL, Bhatt DL,[...]

Clinical Triage of Individuals With Warning Symptoms of Imminent Cardiac Arrest

Reinier K, Chugh H, Kadiyala V, Sargsyan A, Uy-Evanado A, Nakamura K, Heckard E, Mathias M, Grogan T, Elashoff D, Salvucci A, Jui J, Chugh[...]

Nuclear mechanotransduction: tools for mechanical perturbation and chromatin characterization

Soto J, Origer N, Wu Y, Cardenas Benitez B, Massad R, Rahgoshay D, Lee A, Downing T, Li S. Nuclear mechanotransduction: tools for mechanical perturbation[...]